Oak Ridge Investments LLC Has $833,000 Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Oak Ridge Investments LLC cut its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 3.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,391 shares of the biopharmaceutical company’s stock after selling 448 shares during the period. Oak Ridge Investments LLC’s holdings in Intra-Cellular Therapies were worth $833,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Intra-Cellular Therapies by 1.4% in the first quarter. Vanguard Group Inc. now owns 9,225,981 shares of the biopharmaceutical company’s stock valued at $638,438,000 after buying an additional 131,679 shares during the period. Avoro Capital Advisors LLC increased its stake in shares of Intra-Cellular Therapies by 21.2% during the second quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock worth $205,470,000 after purchasing an additional 525,000 shares during the period. Clearbridge Investments LLC increased its stake in shares of Intra-Cellular Therapies by 12.3% during the first quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock worth $120,723,000 after purchasing an additional 191,416 shares during the period. Perceptive Advisors LLC increased its stake in shares of Intra-Cellular Therapies by 62.6% during the second quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock worth $117,557,000 after purchasing an additional 661,052 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Intra-Cellular Therapies by 214.5% during the second quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company’s stock worth $60,895,000 after purchasing an additional 606,358 shares during the period. 92.33% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 53,013 shares of the firm’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $80,970,388.85. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Intra-Cellular Therapies news, EVP Mark Neumann sold 18,714 shares of Intra-Cellular Therapies stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the transaction, the executive vice president now directly owns 29,700 shares of the company’s stock, valued at approximately $2,229,876. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Sharon Mates sold 53,013 shares of Intra-Cellular Therapies stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total value of $4,010,433.45. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $80,970,388.85. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 175,316 shares of company stock valued at $13,037,345 in the last 90 days. 2.60% of the stock is owned by corporate insiders.

Intra-Cellular Therapies Stock Performance

Shares of ITCI stock opened at $86.54 on Friday. The stock’s fifty day moving average price is $74.94 and its two-hundred day moving average price is $73.13. The company has a market cap of $9.14 billion, a PE ratio of -99.47 and a beta of 1.00. Intra-Cellular Therapies, Inc. has a fifty-two week low of $50.87 and a fifty-two week high of $88.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 11.09%. The firm had revenue of $175.40 million for the quarter, compared to analyst estimates of $172.30 million. During the same period last year, the business earned ($0.25) EPS. The company’s revenue was up 39.0% compared to the same quarter last year. On average, equities analysts predict that Intra-Cellular Therapies, Inc. will post -0.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ITCI has been the topic of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday. Morgan Stanley raised their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Royal Bank of Canada raised their price objective on Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. UBS Group lowered their price objective on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Finally, The Goldman Sachs Group lowered their price objective on Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, Intra-Cellular Therapies currently has an average rating of “Moderate Buy” and an average target price of $96.62.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.